Caribou Biosciences (CRBU) Free Cash Flow (2020 - 2026)

Caribou Biosciences (CRBU) has reported Free Cash Flow for 7 consecutive years, with -$27.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 28.55% year-over-year to -$27.0 million; the TTM figure through Mar 2026 stood at -$101.6 million (up 28.57% YoY), while the FY2025 annual figure was -$112.4 million, up 21.48% from the prior year.
• Free Cash Flow declined to -$27.0 million in Q1 2026 per CRBU's latest filing, from -$20.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$18.1 million in Q2 2023 and bottomed at -$40.0 million in Q4 2024.
• Historically, Free Cash Flow has averaged -$28.2 million across 5 years, with a median of -$27.0 million in 2026.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 210.37% — and 2025, when it jumped 48.53%.
• Caribou Biosciences' Free Cash Flow stood at -$21.6 million in 2022, then slipped by 9.67% to -$23.7 million in 2023, then sank by 68.99% to -$40.0 million in 2024, then surged by 48.53% to -$20.6 million in 2025, then slumped by 31.14% to -$27.0 million in 2026.
• Business Quant data shows CRBU's Free Cash Flow at -$27.0 million in Q1 2026, -$20.6 million in Q4 2025, and -$26.7 million in Q3 2025.